XBiotech Inc
Company Profile
Business description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
stocks
ASX share’s growth story intact despite supply constraints
stocks
ASX healthcare giant rallies despite a fall in profits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.80 | 11.60 | -0.12% |
| CAC 40 | 8,453.09 | 48.82 | -0.57% |
| DAX 40 | 25,983.04 | 108.29 | -0.42% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,748.16 | 4.81 | 0.04% |
| HKSE | 25,864.65 | 166.16 | 0.65% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,011.95 | 204.84 | -0.31% |
| NZX 50 Index | 13,938.00 | 18.18 | 0.13% |
| S&P 500 | 7,641.16 | 66.82 | -0.87% |
| S&P/ASX 200 | 9,061.20 | 4.60 | -0.05% |
| SSE Composite Index | 3,903.81 | 0.08 | 0.00% |